

TABLE OF CONTENTS

Infections in Immunocompromised Patients I 1
Infections in Immunocompromised Patients I Panel 3

Cytomegalovirus

By Maressa Santarossa, Pharm.D., BCPS, BCIDP

Introduction 7
Risk Factors for and Pathogenesis of CMV 8
Prophylaxis and Preemptive Therapy Against CMV 9
Diagnosis of CMV Infection and Disease 12
Treatment of CMV Infection and Disease 13
Conclusion 18
References 18
Self-Assessment Questions 22

Candidemia and Invasive Candidiasis

By Christine R. Hanks, Pharm.D., BCIDP

Introduction 27
Diagnosis 29
Antifungal Drugs Used for Candidiasis 30
Clinical Guideline Recommendations for Candidiasis Based on Clinical Manifestation 35
Prophylaxis of Candidemia and Candidiasis in At-Risk Populations 41
Role of Preemptive and Empiric Therapy in Suspected Invasive Candidiasis 42
Conclusion 44
References 45
Self-Assessment Questions (SAQs) 48

Infections in Immunocompromised Patients II 53
Infections in Immunocompromised Patients II Panel 55

Invasive Mold Infections

By Miranda So, Pharm.D.

Introduction 59
Invasive mold infections 59
Aspergillosis 59
Mucormycosis 61
Fusariosis 62
Scedosporiosis 62
Diagnosis of Invasive Mold Infections 63
Antifungal Agents with Antimold Activity 66
Pharmacology of Antifungals 66
Antifungal Pharmacology 69
Comparative Data and Place in Therapy of Antimold Antifungals 75
Summary of Clinical Practice Guideline Recommendations for Invasive Mold Infections 79
Conclusion 84
References 85
Self-Assessment Questions 91

Evaluation of Antibiotic Allergies

By Mary L. Staicu, Pharm.D., BCIDP

Introduction 95
Immunology in the Setting of Antibiotic Hypersensitivity 96
Classification of Immunologically Mediated Drug Reactions 99
Risk Factors Associated with Antibiotic Hypersensitivity 101
Clinical Evaluation and Diagnosis of Drug Hypersensitivity 104
Treatment of Patients with Drug Hypersensitivities 106
Antimicrobials Commonly Associated with Drug Hypersensitivity Reactions 110
Conclusion 119
References 119
Self-Assessment Questions 123

The Link Between Stewardship Strategies and Antimicrobial Resistance

By Madeline King, Pharm.D., BCIDP

Introduction 127
Linking AMR to AS 129
Specific AS Strategies to Reduce Prevalence of AMR 131
Conclusion 142
References 142
Self-Assessment Questions 147

Infections in Immunocompromised Patients III 153
Infections in Immunocompromised Patients III Panel 155

Interactive Case: Asymptomatic Bacteriuria

By Alexandra M. Hanretty, Pharm.D.

Interactive Case: Asymptomatic Bacteriuria 159
Hyperlink to Activity 159
Self-Assessment Questions 163

Interactive Case: *Nocardia* and Atypical Mycobacteria Infections

By Pavithra Srinivas, Pharm.D., BCPS, BCIDP, AAHIVP; and Eric Wenzler, Pharm.D., BCPS, BCIDP, AAHIVP

Interactive Case: *Nocardia* and Atypical Mycobacteria Infections 167
Hyperlink to Activity 168
Self-Assessment Questions 172

Interactive Case: Immunization in the Immunocompromised Host

By Christopher McCoy, Pharm.D., BCPS-AQ ID, BCIDP

Interactive Case: Immunization in the Immunocompromised Host 177
Hyperlink to Activity 177
Self-Assessment Questions 181